Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein.
Animals
Antibodies, Monoclonal
/ pharmacology
Antibodies, Neutralizing
/ pharmacology
Antibody Specificity
Antiviral Agents
/ pharmacology
Chlorocebus aethiops
Cross Reactions
Disease Models, Animal
Drug Therapy, Combination
Ephrin-B2
/ antagonists & inhibitors
Ephrin-B3
/ antagonists & inhibitors
Female
Henipavirus
/ pathogenicity
Henipavirus Infections
/ immunology
Host-Pathogen Interactions
Humans
Mesocricetus
Receptors, Virus
/ antagonists & inhibitors
Vero Cells
B lymphocytes
Hendra virus
Nipah virus
antigen-antibody reactions
epitopes
henipavirus infections
monoclonal antibodies
therapy
viral antibodies
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
31 08 2021
31 08 2021
Historique:
received:
27
02
2021
revised:
25
05
2021
accepted:
05
08
2021
entrez:
1
9
2021
pubmed:
2
9
2021
medline:
15
2
2022
Statut:
ppublish
Résumé
Hendra virus and Nipah virus (NiV), members of the Henipavirus (HNV) genus, are zoonotic paramyxoviruses known to cause severe disease across six mammalian orders, including humans. We isolated a panel of human monoclonal antibodies (mAbs) from the B cells of an individual with prior exposure to equine Hendra virus (HeV) vaccine, targeting distinct antigenic sites. The most potent class of cross-reactive antibodies achieves neutralization by blocking viral attachment to the host cell receptors ephrin-B2 and ephrin-B3, with a second class being enhanced by receptor binding. mAbs from both classes display synergistic activity in vitro. In a stringent hamster model of NiV Bangladesh (NiV
Identifiants
pubmed: 34469726
pii: S2211-1247(21)01066-4
doi: 10.1016/j.celrep.2021.109628
pmc: PMC8527959
mid: NIHMS1737337
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antiviral Agents
0
Ephrin-B2
0
Ephrin-B3
0
Receptors, Virus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109628Subventions
Organisme : NIAID NIH HHS
ID : F31 AI152332
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142764
Pays : United States
Organisme : NIAID NIH HHS
ID : UC7 AI094660
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002243
Pays : United States
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.E.C. has served as a consultant for Luna Biologics, is a member of the Scientific Advisory Board of Meissa Vaccines, and is Founder of IDBiologics. The Crowe laboratory at Vanderbilt University Medical Center has received unrelated sponsored research agreements from Takeda, IDBiologics, and AstraZeneca. E.A.K., Z.A.B., and B.R.W. are employees and shareholders of Mapp. L.Z. is an employee, shareholder, and co-owner of Mapp. C.C.B. is a US federal employee, and C.C.B. and M.A. are co-inventors on US and foreign patents pertaining to Cedar virus and methods of use and recombinant Cedar virus chimeras, whose assignees are the US as represented by the Henry M. Jackson Foundation for the Advancement of Military Medicine (Bethesda, MD, USA). The remaining authors declare no competing interests.
Références
Emerg Infect Dis. 2006 Feb;12(2):235-40
pubmed: 16494748
PLoS Pathog. 2013;9(10):e1003684
pubmed: 24130486
Global Health. 2017 Feb 8;13(1):9
pubmed: 28179007
J Infect Dis. 2019 Apr 8;219(8):1264-1273
pubmed: 30496483
mSphere. 2020 Jul 8;5(4):
pubmed: 32641430
J Virol. 2006 Feb;80(4):1972-8
pubmed: 16439553
Emerg Infect Dis. 2007 Jul;13(7):1031-7
pubmed: 18214175
Science. 1995 Apr 7;268(5207):94-7
pubmed: 7701348
J Gen Virol. 2012 Apr;93(Pt 4):850-856
pubmed: 22205718
J Infect Dis. 2008 Mar 15;197(6):846-53
pubmed: 18271743
Methods Protoc. 2018 Jan 22;1(1):
pubmed: 31164554
Trends Microbiol. 2011 Aug;19(8):389-99
pubmed: 21511478
Nat Struct Mol Biol. 2019 Oct;26(10):980-987
pubmed: 31570878
J Gen Virol. 2015 Jan;96(Pt 1):24-29
pubmed: 25228492
Sci Rep. 2017 Aug 15;7(1):8226
pubmed: 28811483
Nat Biotechnol. 2007 Nov;25(11):1290-7
pubmed: 17934452
Am J Trop Med Hyg. 2011 Nov;85(5):946-51
pubmed: 22049055
Pediatr Infect Dis J. 1999 Mar;18(3):223-31
pubmed: 10093942
J Virol. 2014 May;88(9):4624-31
pubmed: 24522928
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Methods Enzymol. 2010;481:109-26
pubmed: 20887855
Ecol Lett. 2015 Nov;18(11):1153-1162
pubmed: 26299267
PLoS Pathog. 2009 Oct;5(10):e1000642
pubmed: 19888339
Sci Transl Med. 2011 Oct 19;3(105):105ra103
pubmed: 22013123
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Infect Dis. 2019 May 24;219(12):1867-1878
pubmed: 30364984
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Proc Biol Sci. 2015 Jan 7;282(1798):20142124
pubmed: 25392474
Curr Opin Virol. 2016 Feb;16:120-125
pubmed: 26978066
Cell. 2020 Sep 3;182(5):1077-1092
pubmed: 32846157
J Gen Virol. 2019 Dec;100(12):1593-1594
pubmed: 31609197
Nucleic Acids Res. 2016 Jul 8;44(W1):W474-8
pubmed: 27131379
Med J Aust. 1995 Jun 19;162(12):642-5
pubmed: 7603375
PLoS Pathog. 2013;9(11):e1003770
pubmed: 24278018
Emerg Infect Dis. 2014 Mar;20(3):372-9
pubmed: 24572697
J Virol. 2006 Jan;80(2):891-9
pubmed: 16378991
J Infect Dis. 2020 May 11;221(Suppl 4):S471-S479
pubmed: 31686101
Microbes Infect. 2002 Feb;4(2):145-51
pubmed: 11880045
J Infect Dis. 2016 Feb 1;213(3):448-55
pubmed: 26357909
Bioinformatics. 2017 Aug 1;33(15):2413-2415
pubmed: 28379339
J Virol. 2013 Mar;87(6):3284-94
pubmed: 23302882
Emerg Microbes Infect. 2019;8(1):1314-1323
pubmed: 31495335
Emerg Infect Dis. 2019 Jun;25(6):1144-1152
pubmed: 31107231
Sci Rep. 2016 Aug 03;6:30916
pubmed: 27484128
Sci Transl Med. 2014 Jun 25;6(242):242ra82
pubmed: 24964990
J Biol Chem. 2009 Jan 16;284(3):1628-35
pubmed: 19019819
Ann N Y Acad Sci. 2018 Oct;1429(1):78-99
pubmed: 30138535
Emerg Infect Dis. 1995 Jan-Mar;1(1):31-3
pubmed: 8903153
Annu Rev Virol. 2020 Sep 29;7(1):447-473
pubmed: 32991264
Sci Transl Med. 2012 Aug 8;4(146):146ra107
pubmed: 22875827
Biol Proced Online. 2004;6:23-34
pubmed: 15103397
Cell Host Microbe. 2017 Aug 9;22(2):193-206
pubmed: 28799905
Ecohealth. 2018 Sep;15(3):509-525
pubmed: 29556762
Methods. 2019 Feb 1;154:77-86
pubmed: 30102989
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
J Virol. 2011 Aug;85(15):7658-71
pubmed: 21593160
PLoS One. 2014 Mar 20;9(3):e92451
pubmed: 24651868
Cell. 2020 Dec 10;183(6):1536-1550.e17
pubmed: 33306954
NPJ Vaccines. 2021 Feb 8;6(1):23
pubmed: 33558494
Nat Commun. 2012 Apr 24;3:796
pubmed: 22531181
J Clin Invest. 2017 Jun 1;127(6):2249-2261
pubmed: 28463232
Virology. 2002 Jun 20;298(1):146-59
pubmed: 12093182
J Virol. 2004 Jan;78(2):834-40
pubmed: 14694115
Science. 2015 Jul 3;349(6243):88-91
pubmed: 26138979
Lancet. 1999 Oct 9;354(9186):1257-9
pubmed: 10520635
J Transl Med. 2014 Dec 13;12:346
pubmed: 25496375
J Virol. 2010 Jun;84(12):6208-17
pubmed: 20375167
Lancet Infect Dis. 2020 Apr;20(4):445-454
pubmed: 32027842
Viruses. 2020 Apr 20;12(4):
pubmed: 32325930
J Exp Med. 1980 Feb 1;151(2):275-88
pubmed: 6766174
J Infect Dis. 2020 May 11;221(Suppl 4):S460-S470
pubmed: 32108876
Cell Rep. 2017 Apr 11;19(2):413-424
pubmed: 28402862
Am J Pathol. 2003 Nov;163(5):2127-37
pubmed: 14578210
Virol J. 2012 Oct 19;9:240
pubmed: 23082748
Emerg Infect Dis. 2012 Dec;18(12):1983-93
pubmed: 23171621
J Gen Virol. 2015 Jul;96(Pt 7):1619-25
pubmed: 25701824
J Gen Virol. 2000 Aug;81(Pt 8):1927-1932
pubmed: 10900029